Lpath Incorporated

• Home
• About Lpath
  • Brief Overview
  • Company Summary
  • Pipeline
  • Our Novel Approach
  • Patent Portfolio
  • Pioneers of the Category
• The Lpath Team
  • Executive Team
  • Board of Directors
  • Advisory Boards
    • Clinical
    • Ocular
    • Scientific
• The Science: An Overview
  • Technical Overview
    • S1P Target
    • LPA Target
  • Science of Cancer
  • Angiogenesis Tutorial
  • Publications/Presentations/ Grants
• Investor Center
  • Investor Overview
  • Stock Information
  • News Releases
  • Calendar of Events
  • SEC Filings
  • Investor FAQ
  • Request Information
  • Email Alerts
• Legal, Important Notices
• Contact Us

Ocular Advisory Board

 

David S. Boyer, M.D.

Background: Dr. Boyer is a practising ophthalmologist who specializes in the treatment of diseases of the retina and vitreous. Dr. Boyer is a Senior Partner at the Retina-Vitreous Associates Medical Group and a Clinical Associate Professor at the University of Southern California. He also has an extensive research background involving trials for age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis. Dr. Boyer has been on the advisory boards for Alcon, Novartis, Eyetech/Pfizer, Genentech, Neurotech and the Macular Degeneration Partnership and is a reviewer for several ophthalmology and diabetes medical publications including Archives of Ophthalmology, American Journal of Ophthalmology, Diabetes Care, and Ophthalmology. Throughout his career, Dr. Boyer has been honoured by prestigious organizations including the American Academy of Ophthalmology (Board of Trustees Honor Award Certificate) and Retinitis Pigmentosa International (1996 Jules Stein Living Tribute Award).

Jeffrey Heier, M.D.

Background: Dr. Heier is Assistant Professor, Tufts University School of Medicine, and Clinical Instructor, Harvard Medical School. He is also a vitreoretinal specialist for Ophthalmic Consultants of Boston. Dr. Heier was one of the lead investigators of Genentech's MARINA and FOCUS studies and has served as an advisor or consultant to Genentech, Eyetech Pharmaceuticals, Pfizer, VisionCare Ophthalmic Technologies, OXiGENE, Jerini, Novartis, iScience Surgical Corp., Genzyme, and Carl Zeiss Meditec. Surgery Branch. Prior to joining the Yale University School of Medicine, he was Vice President for Clinical Affairs at Vion Pharmaceuticals.

Peter K. Kaiser, MD

Background: Dr. Kaiser, MD, is a Staff member of the vitreoretinal faculty of the Cole Eye Institute in the Department of Ophthalmology at Cleveland Clinic's main campus. He was appointed in 1997.  Dr. Kaiser is actively involved in retinal clinical research, and is study chairman of 4 major, multi-center, international clinical trials and is a principal investigator in multiple other trials. Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences.

Baruch Kupperman, M.D., Ph.D.

Background: Dr. Kupperman is a Professor and Chief of the Retina Service at the University of California, Irvine. He is the principal investigator at UCI for several multicenter national trials evaluating new drugs and devices for the treatment of diabetic retinopathy, age-related macular degeneration, and the ocular complications of AIDS.

Jason Slakter, M.D.

Background: Jason Slakter, M.D., is a board-certified vitreoretinal surgeon and macular-disease specialist and currently practices at the Vitreous-Retina-Macula Consultants in New York City. In addition, he is a Clinical Professor of Ophthalmology at NYU's School of Medicine and an attending surgeon and Surgeon Director at the Manhattan Eye, Ear, and Throat Hospital in New York. Dr. Slakter is an internationally recognized retinal specialist whose chief research interests relate to exudative AMD, retinal vascular disease, and central serous chorioretinopathy. He serves on the medical advisory boards of many biotechs and pharmaceutical companies involved in these areas. Dr. Slakter is Editor-in-Chief of Retinal Physician and is on the editorial board of Retina.